Deltagen

Deltagen Current Liabilities

The Current Liabilities of Deltagen (DGEN) as of Nov 3, 2026 is 129,000.00 USD. In the previous year, Current Liabilities was 127,686.96 USD — a change of 1.03% (higher).

Current Liabilities

129,000.00USD

YoY

1.03%

Last updated:

Current Liabilities of Deltagen is 2015 129,000.00 USD. Current Liabilities of Deltagen was 2014 127,686.96 USD. It decreases by 1.03% higher compared to the previous year.

The Deltagen Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2008
566,000.00 USD
Jan 1, 2009
254,000.00 USD
Jan 1, 2010
410,000.00 USD
Jan 1, 2011
574,000.00 USD
Jan 1, 2012
435,101.19 USD
Jan 1, 2013
606,000.00 USD
Jan 1, 2014
127,686.96 USD
Jan 1, 2015
129,000.00 USD
The Deltagen Current Liabilities history
YEARCurrent LiabilitiesYoY
129,000.00USD+1.03%
127,686.96USD-78.93%
606,000.00USD+39.28%
435,101.19USD-24.20%
574,000.00USD+40.00%
410,000.00USD+61.42%
254,000.00USD-55.12%
566,000.00USD-34.57%
865,000.00USD-24.12%
1.14 MUSD-81.11%
6.04 MUSD-90.79%
65.52 MUSD+216.72%
20.69 MUSD+11.51%
18.55 MUSD+167.37%
6.94 MUSD+6,839.00%
100,000.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Deltagen Stock analysis

What does Deltagen do? Deltagen Inc is a leading biotechnology company focused on drug discovery and the development of novel therapies. The company was founded in 1996 by a group of scientists and is headquartered in San Francisco, California. The founders recognized the potential of genetic research and developed innovative technologies for identifying target molecules for drug development. Over the years, they acquired numerous patents and heavily invested in research and development. Deltagen Inc specializes in two core areas: genomic research and drug discovery. In the field of genomic research, the company offers services for systematic analysis of gene functions. This includes identification of target molecules, development of drug candidates, and validation of drug targets. In the field of drug discovery, Deltagen Inc focuses on developing novel therapies for a variety of diseases. The company utilizes advanced technologies and innovative research approaches to identify and validate potential drug candidates. Their goal is to develop groundbreaking medications that significantly improve patient's lives. Another important area of Deltagen Inc is diagnostics. The company offers tests for various diseases, including cancer, neurological disorders, and metabolic disorders. These tests are based on genetic analysis and can aid in early detection of diseases and enable targeted treatment. Deltagen Inc works closely with the pharmaceutical industry and other partners to advance drug development. The company has established numerous collaborations and licensing agreements with leading pharmaceutical companies and offers a wide range of products and services for drug development. Deltagen Inc's products include antibodies and other biomolecules that can be used for the treatment of diseases such as cancer, autoimmune disorders, and infectious diseases. The company also develops innovative therapy approaches based on RNA interference and gene therapy. Deltagen Inc is a company with a strong culture of innovation, constantly striving to explore new avenues and evolve. The founders and the entire team have a passion for science and the potential it has for improving the health and well-being of people. Deltagen Inc emphasizes close collaboration with customers and partners to jointly develop and market innovative solutions. The company takes pride in being part of an industry that contributes to improving the lives of patients worldwide. Deltagen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Deltagen stock

Current Liabilities of Deltagen is 129,000.00 USD in 2015.

Current Liabilities of Deltagen changed from 127,686.96 USD to 129,000.00 USD, representing a 1.03% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Deltagen since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Deltagen historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Deltagen

All Key Metrics — Deltagen